About 

Universe Pharmaceuticals 株価情報 (NASDAQ: UPC)

最新ニュース Universe Pharmaceuticals (NASDAQ:UPC) 株価情報

Universe Pharmaceuticals

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals Inc

UNI-PRESIDENT C/H UNS/ADR by Uni-President China Holdings Ltd.

Uni-President China Holdings Ltd

UNIVERSAL POTASH CORP by Universal Potash Corp.

Universal Potash Corp

FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) has outperformed the market over the past 20 years by 5.78% on an annualized basis producing an average annual return of 13.96%. Currently, FactSet Research Systems has a market capitalization of $16.61 billion. 
Buying $1000 In FDS: If an investor had bought $1000 of FDS stock 20 years ago, it would be worth $13,318.60 today based on a price of $436.85 for FDS at the time of writing.
<h3>FactSet Research Systems's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741989638_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In FactSet Research Systems 20 Years Ago Would Be Worth Today

Harold Hamm, oil magnate and founder of Continental Resources, issued a stark warning: if oil prices remain at current levels, drilling in key U.S. shale fields could <a href="https://www.benzinga.com/25/03/44168987/oil-prices-hit-multi-year-lows">come to a standstill. </a>
The Details: Speaking at CERAWeek in Houston, Hamm emphasized that with oil prices hovering near $65 per barrel, many fields are already struggling to remain viable.&nbsp;
"When you get below the cost of supply, you can't ‘drill, baby, drill,'" he told Bloomberg, per OilPrice.com.
Read Next: <a href="https://www.benzinga.com/government/regulations/25/03/44310724/doge-cuts-to-ftc-sow-confusion-in-case-against-amazon">DOGE Cuts To FTC Sow Confusion In Case Against Amazon</a>&nbsp;
While industry leaders have applauded the rollback of Biden-era climate regulations, Trump's trade policies—particularly his tariff disputes with Canada—are creating uncertainty and further pressuring crude oil prices. Trump has described the lower prices as "phenomenal news," but many in the oil sector are expressing concern.&nbsp;
"There are a lot of fields that are getting to the point that's real tough to keep that cost of supply down," Hamm told Bloomberg Television.&nbsp;
"When you get down to that $50 oil that you talked about, then you're below the point where you're going to ‘drill, baby, drill.'"
ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) CEO Ryan Lance also highlighted inflationary pressures and investor anxiety over Trump's unpredictable trade policies affecting the industry.&nbsp;
Scott Sheffield, former CEO of Pioneer Natural Resources, told Bloomberg Television that the price publicly traded oil drillers need to cover costs and turn a profit is between $50 and $55 a barrel. 
The oil industry could be at a turning point as low oil prices benefit consumers but pose significant challenges for producers. 
The United States Oil Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) ETF, tracking the daily price movements of light, sweet crude oil, is down more than 4% in 2025. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44253259/uncertainty-rocks-the-trump-trade-how-maga-seven-stocks-look-now">Uncertainty Rocks The Trump Trade: How &#8216;MAGA Seven&#8217; Stocks Look Now</a></li>
</ul>
Image: Shutterstock&nbsp;

Specialty ETFs

Commodities

Management

Markets

ETFs

Oil Titan Harold Hamm Warns Drilling Could Stop If Oil Prices Remain Low: 'You Can't Drill, Baby, Drill'

Castellum, Inc. (the "Company" or "Castellum") (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced that it intends to offer and sell shares of its common stock and warrants exercisable into shares of the Company's common stock, in a public offering. All of the shares of common stock are being offered by Castellum. Castellum initially intends to use the net proceeds of the offering for working capital and general corporate purposes. Consummation of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Maxim Group LLC is acting as the sole placement agent for the offering on a reasonable best-efforts basis.

Offerings

Castellum Announces Proposed Public Offering Of Common Stock And Warrants; No Size Or Amount Disclosed

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) has outperformed the market over the past 5 years by 4.97% on an annualized basis producing an average annual return of 22.32%. Currently, Simon Property Group has a market capitalization of $52.60 billion. 
Buying $1000 In SPG: If an investor had bought $1000 of SPG stock 5 years ago, it would be worth $2,450.37 today based on a price of $161.21 for SPG at the time of writing.
<h3>Simon Property Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741988720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Simon Property Group Stock In The Last 5 Years

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.68% on an annualized basis producing an average annual return of 22.06%. Currently, Meta Platforms has a market capitalization of $1.54 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 10 years ago, it would be worth $7,509.58 today based on a price of $607.60 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741987839_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Meta Platforms 10 Years Ago Would Be Worth Today

GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) has outperformed the market over the past 10 years by 10.63% on an annualized basis producing an average annual return of 21.02%. Currently, GoDaddy has a market capitalization of $24.90 billion. 
Buying $100 In GDDY: If an investor had bought $100 of GDDY stock 10 years ago, it would be worth $673.61 today based on a price of $176.15 for GDDY at the time of writing.
<h3>GoDaddy's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741986909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GDDY

Here's How Much You Would Have Made Owning GoDaddy Stock In The Last 10 Years

BBWI

Bath & Body Works Files For Mixed Shelf Offering; Size Not Disclosed

Coffee Holding Co Files For Mixed Shelf Offering Of Up To $30M

On March&nbsp;13, 2025, Radius Recycling,&nbsp;Inc., an Oregon corporation (&quot;Radius&quot;), Toyota Tsusho America,&nbsp;Inc., a New York corporation (&quot;Parent&quot;), and TAI Merger Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (&quot;Merger Sub&quot;), entered into an Agreement and Plan of Merger (the &quot;Merger Agreement&quot;), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Radius (the &quot;Merger&quot;), with Radius continuing as the surviving corporation in the Merger as a wholly owned subsidiary of Parent. The Board of Directors of Radius has approved the Merger Agreement and the transactions contemplated thereby, including the Merger.
&nbsp;
On the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the &quot;Effective Time&quot;), and as a result of the Merger, each share of common stock of Radius (&quot;Radius Common Stock&quot;) that is issued and outstanding immediately prior to the Effective Time (other than any shares of Class&nbsp;B common stock of Radius for which dissenters&#39; rights have been properly exercised and perfected and not withdrawn) will be converted into the right to receive $30.00 in cash (the &quot;Merger Consideration&quot;), without interest, and less any applicable withholding taxes.

Contracts

RDUS

Radius Recycling To Pay $27.2M Termination Fee To Toyota Tsusho America If Deal Terminated Under Specified Circumstances

GE Aerospace Secures $1.8B U.S. Air Force Contract For F110 Engines

<h3>Gainers</h3>
<ul>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares moved upwards by 55.0% to $0.82 during Friday's after-market session. The company's market cap stands at $235.5 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares moved upwards by 10.84% to $0.41. The company's market cap stands at $2.5 million. </li>
<li>Garrett Motion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) shares moved upwards by 9.46% to $9.8. The market value of their outstanding shares is at $2.0 billion. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock rose 6.08% to $1.22. The market value of their outstanding shares is at $23.4 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock rose 4.99% to $0.4. The company's market cap stands at $117.2 million. </li>
<li>Lotus Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) shares moved upwards by 4.99% to $1.68. The company's market cap stands at $1.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) stock fell 8.1% to $2.05 during Friday's after-market session. The market value of their outstanding shares is at $59.2 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares declined by 5.52% to $2.91. The company's market cap stands at $8.2 million. </li>
<li>Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) stock declined by 5.33% to $2.31. The company's market cap stands at $69.6 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) stock declined by 4.41% to $8.0. The company's market cap stands at $102.2 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares declined by 4.29% to $0.27. The company's market cap stands at $6.4 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock fell 4.29% to $0.87. The market value of their outstanding shares is at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMBO

NWTN

PLCE

SBET

TLYS

XELB

12 Consumer Discretionary Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares increased by 30.1% to $1.77 during Friday's after-market session. The market value of their outstanding shares is at $280.2 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock rose 8.77% to $3.1. The market value of their outstanding shares is at $3.0 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares rose 8.52% to $3.69. The company's market cap stands at $3.3 million. </li>
<li>Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) shares moved upwards by 7.66% to $6.99. The company's market cap stands at $116.7 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock moved upwards by 7.44% to $3.75. The company's market cap stands at $18.1 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares moved upwards by 7.41% to $0.8. The company's market cap stands at $44.1 million. The company's, Q4 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock declined by 9.4% to $0.13 during Friday's after-market session. The company's market cap stands at $2.2 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares fell 7.1% to $0.57. The market value of their outstanding shares is at $13.5 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock decreased by 6.79% to $0.25. The company's market cap stands at $1.7 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 6.56% to $0.42. The market value of their outstanding shares is at $2.6 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock fell 6.49% to $0.35. The company's market cap stands at $1.7 million. </li>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) stock declined by 6.45% to $1.16. The company's market cap stands at $116.1 million. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

CLLS

COYA

HCTI

HSCS

PRLD

PTIX

REVB

SHPH

SNTI

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares increased by 6.2% to $2.4 during Friday's after-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li>Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) stock rose 5.78% to $11.15. The company's market cap stands at $584.7 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) shares moved upwards by 5.15% to $1.02. The company's market cap stands at $96.2 million. </li>
<li>Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) shares rose 5.06% to $5.81. The market value of their outstanding shares is at $668.7 million. </li>
<li>Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) stock increased by 4.99% to $109.65. The market value of their outstanding shares is at $5.3 billion. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock increased by 4.7% to $0.22. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) stock decreased by 12.8% to $0.4 during Friday's after-market session. The company's market cap stands at $7.2 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) stock fell 7.53% to $3.35. The company's market cap stands at $51.1 million. </li>
<li>Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) stock fell 6.86% to $0.58. The company's market cap stands at $30.4 million. </li>
<li>SUNation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) shares decreased by 6.78% to $0.49. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock fell 6.59% to $0.71. The market value of their outstanding shares is at $25.4 million. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock fell 5.72% to $0.33. The market value of their outstanding shares is at $5.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRC

AREB

BGLC

GPUS

ILAG

LASE

SAIC

SDST

SUNE

VCIG

VLRS

12 Industrials Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares rose 8.6% to $0.4 during Friday's after-market session. The company's market cap stands at $16.6 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) stock increased by 5.68% to $0.93. The company's market cap stands at $34.4 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares rose 5.45% to $0.22. The market value of their outstanding shares is at $15.0 million. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) shares rose 5.3% to $1.19. The market value of their outstanding shares is at $189.2 million. </li>
<li>Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) stock rose 5.0% to $11.76. The company's market cap stands at $855.7 million. </li>
<li>Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) shares rose 4.97% to $3.59. The market value of their outstanding shares is at $319.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) stock declined by 6.7% to $3.45 during Friday's after-market session. The company's market cap stands at $32.4 million. </li>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock fell 4.99% to $0.28. The company's market cap stands at $1.6 million. </li>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) stock decreased by 4.97% to $3.83. The company's market cap stands at $348.2 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares fell 4.89% to $0.52. The market value of their outstanding shares is at $24.0 million. </li>
<li>Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) stock decreased by 4.87% to $2.15. The market value of their outstanding shares is at $105.5 million. </li>
<li>DatChat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares declined by 4.65% to $2.0. The company's market cap stands at $8.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUUD

BNAI

DATS

EXFY

GRYP

MOBX

Nuveen California Dividend Advantage Municipal Fund 2

RMNI

TZUP

WEAV

WRAP

12 Information Technology Stocks Moving In Friday's After-Market Session

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and SpaceX have both raised <a href="https://www.benzinga.com/topic/tariffs">concerns about the tariffs</a>, warning that retaliatory measures could harm their respective industries. 
The companies, both led by Elon Musk, submitted letters to U.S. Trade Representative Jamison Greer urging consideration of the broader economic impacts when shaping trade strategies, <a href="https://www.cnbc.com/2025/03/14/elon-musks-spacex-tesla-lobby-trump-trade-rep-on-tariffs.html">CNBC</a> reports.
What Happened: In its letter, Tesla warned that previous U.S. trade actions had increased costs for vehicles both in the domestic market and abroad, weakening the company&#8217;s competitiveness, ABC News <a href="https://abcnews.go.com/US/tesla-letter-tells-trump-administration-worried-tariffs/story?id=119796605">reports</a>. Meanwhile, SpaceX highlighted concerns that tariffs on key spacecraft components could disrupt production and add significant costs to future projects. 
Both companies stressed that retaliatory tariffs imposed by China and Canada were placing additional strain on U.S. exporters.
Tesla's letter, as reported by ABC News, did not identify its author, and it&#8217;s unclear whether Musk personally influenced the communication. Musk has not publicly commented on the letters, though he has previously supported reduced government spending. The White House has yet to respond to Tesla and SpaceX&#8217;s concerns. 
Also Read: <a href="https://www.benzinga.com/government/regulations/25/03/44340164/market-bottom-or-another-scared-cat-bounce-wall-street-veteran-remains-skeptical">Market Bottom Or Another &#8216;Scared Cat Bounce&#8217;? Wall Street Veteran Remains Skeptical</a>
Why It Matters: Concerns from Tesla and SpaceX emerge at a turbulent time for Musk's public image. Musk's growing political involvement, including his role in the Trump administration's Department of Government Efficiency, has faced skepticism.
According to a recent CNN/SSRS poll, 62% of respondents believe Musk lacks the necessary experience to influence government changes, while 53% expressed <a href="https://www.benzinga.com/politics/25/03/44319499/elon-musk-disapproval-rating-53-in-new-poll-62-say-tesla-ceo-doesnt-have-right-experience-to-make-changes-to-government">disapproval of his involvement.</a> 
This discontent has coincided with declining Tesla stock prices. Since the start of 2025, Tesla's valuation has fallen over 34%. The drop follows widespread concerns about Musk's dual focus on government work and corporate leadership. Critics argue that his involvement in political matters could further hinder investor confidence.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44337983/economists-react-to-march-consumer-confidence-plunge-this-is-a-horrific-report">&#8216;Horrific Report&#8217;: Economists Warn Consumer Confidence Collapse Signals Economic Trouble</a></li>
</ul>
Photo: Shutterstock

Government

Politics

Tech

TSLA

Tesla, SpaceX Warn Tariffs Could Harm US Innovation And Industry

Analysts' ratings for Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $109.54, with a high estimate of $122.00 and a low estimate of $85.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.52%. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986075_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Crown Castle by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batya Levi</td>
<td>UBS</td>
<td>Maintains</td>
<td>Buy</td>
<td>$118.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$99.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Ric Prentiss</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$122.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Rollins</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$106.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$115.00</td>
<td>-</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$102.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Crown Castle. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Crown Castle compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Crown Castle's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crown Castle analyst ratings.</a>
<h2>Discovering Crown Castle: A Closer Look</h2>
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 90,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest us cities. The company has a very concentrated customer base, with about 75% of its revenue coming from the big three us mobile carriers. Crown Castle operates as a real estate investment trust.
<h3>Key Indicators: Crown Castle's Financial Health</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Crown Castle faced challenges, resulting in a decline of approximately -0.9% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Crown Castle's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 18.34%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Crown Castle's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Crown Castle's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.79%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 5.6, Crown Castle faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On Crown Castle Through 13 Analysts

During the last three months, 15 analysts shared their evaluations of Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Colgate-Palmolive, presenting an average target of $98.47, a high estimate of $112.00, and a low estimate of $83.00. This current average has decreased by 5.5% from the previous average price target of $104.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986049_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Colgate-Palmolive among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Olivia Tong</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$83.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$104.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$121.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Colgate-Palmolive. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Colgate-Palmolive's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Colgate-Palmolive's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>All You Need to Know About Colgate-Palmolive</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>A Deep Dive into Colgate-Palmolive's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Colgate-Palmolive's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -0.1%. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Colgate-Palmolive's ROE excels beyond industry benchmarks, reaching 228.44%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Colgate-Palmolive's ROA excels beyond industry benchmarks, reaching 4.5%. This signifies efficient management of assets and strong financial health.
Debt Management: Colgate-Palmolive's debt-to-equity ratio is notably higher than the industry average. With a ratio of 40.15, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 15 Analysts Discuss Colgate-Palmolive Stock

5 analysts have shared their evaluations of Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Vornado Realty and provided 12-month price targets. The average target is $36.4, accompanied by a high estimate of $48.00 and a low estimate of $28.00. This current average reflects an increase of 12.35% from the previous average price target of $32.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986030_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Vornado Realty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Smotrich</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$32.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Floris Van Dijkum</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Vornado Realty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vornado Realty compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Vornado Realty's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Vornado Realty's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VNO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vornado Realty analyst ratings.</a>
<h2>Discovering Vornado Realty: A Closer Look</h2>
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
<h3>Breaking Down Vornado Realty's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Vornado Realty showcased positive performance, achieving a revenue growth rate of 3.6% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Vornado Realty's net margin excels beyond industry benchmarks, reaching 0.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Vornado Realty's ROE stands out, surpassing industry averages. With an impressive ROE of 0.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Vornado Realty's ROA stands out, surpassing industry averages. With an impressive ROA of 0.01%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Vornado Realty's debt-to-equity ratio surpasses industry norms, standing at 2.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Vornado Realty: Insights From 5 Financial Analysts

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $276.5, along with a high estimate of $301.00 and a low estimate of $251.00. This current average reflects an increase of 5.64% from the previous average price target of $261.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986021_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Cencora is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$274.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>John Belton</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$251.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$301.00</td>
<td>$289.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cencora. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cencora's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/COR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cencora analyst ratings.</a>
<h2>About Cencora</h2>
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
<h3>A Deep Dive into Cencora's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Cencora's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.78% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Cencora's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.6% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 112.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Cencora's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.72% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cencora's debt-to-equity ratio stands notably higher than the industry average, reaching 35.96. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Cencora Stock

4 analysts have shared their evaluations of CareTrust REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CareTrust REIT, revealing an average target of $28.75, a high estimate of $32.00, and a low estimate of $26.00. This current average has decreased by 12.21% from the previous average price target of $32.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1741986012_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of CareTrust REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$26.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareTrust REIT. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CareTrust REIT compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CareTrust REIT's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CareTrust REIT's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CTRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CareTrust REIT analyst ratings.</a>
<h2>Unveiling the Story Behind CareTrust REIT</h2>
CareTrust REIT Inc is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. The company has one reportable segment consisting of investments in healthcare-related real estate assets. It generates revenues by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property.
<h3>CareTrust REIT's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining CareTrust REIT's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.32% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: CareTrust REIT's net margin excels beyond industry benchmarks, reaching 83.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CareTrust REIT's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.95%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CareTrust REIT's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.64%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.14, CareTrust REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTRE

Expert Outlook: CareTrust REIT Through The Eyes Of 4 Analysts

Earnings

Press Releases

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Universe Pharmaceuticals INC Announces Share Consolidation

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering

Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

Comments

Universe Pharmaceuticals

ニュース

最新ニュース Universe Pharmaceuticals (NASDAQ:UPC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル